GW Pharmaceuticals PLC- (NASDAQ:GWPH) insider Douglas B. Snyder sold 5,424 shares of GW Pharmaceuticals PLC- stock in a transaction on Monday, August 19th. The shares were sold at an average price of $13.04, for a total value of $70,728.96. Following the completion of the transaction, the insider now owns 73,740 shares of the company’s stock, valued at $961,569.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Douglas B. Snyder also recently made the following trade(s):
- On Tuesday, July 9th, Douglas B. Snyder sold 4,968 shares of GW Pharmaceuticals PLC- stock. The stock was sold at an average price of $14.42, for a total value of $71,638.56.
Shares of NASDAQ:GWPH traded up $2.01 during trading on Wednesday, hitting $152.86. 318,297 shares of the stock were exchanged, compared to its average volume of 442,404. The company has a fifty day moving average price of $164.38 and a two-hundred day moving average price of $166.74. The company has a market cap of $4.55 billion, a PE ratio of -14.48 and a beta of 2.25. The company has a current ratio of 8.31, a quick ratio of 7.59 and a debt-to-equity ratio of 0.03. GW Pharmaceuticals PLC- has a 12-month low of $90.14 and a 12-month high of $196.00.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.74) by $0.96. The firm had revenue of $72.04 million for the quarter, compared to analyst estimates of $37.28 million. GW Pharmaceuticals PLC- had a negative return on equity of 38.09% and a negative net margin of 101.45%. GW Pharmaceuticals PLC-‘s revenue was up 2096.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.25) EPS. Equities research analysts anticipate that GW Pharmaceuticals PLC- will post -3.84 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Horan Capital Advisors LLC. purchased a new position in GW Pharmaceuticals PLC- in the 1st quarter valued at about $25,000. Kavar Capital Partners LLC acquired a new stake in shares of GW Pharmaceuticals PLC- in the second quarter valued at approximately $26,000. Exane Derivatives acquired a new stake in shares of GW Pharmaceuticals PLC- in the first quarter valued at approximately $28,000. Prestige Wealth Management Group LLC acquired a new stake in shares of GW Pharmaceuticals PLC- in the second quarter valued at approximately $28,000. Finally, TCG Advisors LP acquired a new position in shares of GW Pharmaceuticals PLC- during the first quarter valued at approximately $29,000. Hedge funds and other institutional investors own 80.94% of the company’s stock.
A number of analysts have recently commented on the company. Piper Jaffray Companies lifted their target price on GW Pharmaceuticals PLC- from $185.00 to $210.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $229.00 price objective (up previously from $196.00) on shares of GW Pharmaceuticals PLC- in a report on Tuesday, May 7th. Oppenheimer lifted their price objective on GW Pharmaceuticals PLC- from $234.00 to $239.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. ValuEngine lowered GW Pharmaceuticals PLC- from a “hold” rating to a “sell” rating in a report on Monday, August 12th. Finally, JPMorgan Chase & Co. raised GW Pharmaceuticals PLC- from a “market perform” rating to an “outperform” rating in a report on Wednesday, May 8th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. GW Pharmaceuticals PLC- has an average rating of “Buy” and a consensus target price of $212.70.
About GW Pharmaceuticals PLC-
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.
Featured Article: Compound Interest
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.